Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q00973
UPID:
B4GN1_HUMAN
Alternative names:
(N-acetylneuraminyl)-galactosylglucosylceramide; GM2/GD2 synthase; GalNAc-T
Alternative UPACC:
Q00973; B4DE26; Q8N636
Background:
Beta-1,4 N-acetylgalactosaminyltransferase 1, also known as GM2/GD2 synthase or GalNAc-T, plays a crucial role in the biosynthesis of gangliosides GM2, GD2, GT2, and GA2. These complex molecules are essential components of cell membranes, influencing cell signaling and interaction. The protein's alternative names include (N-acetylneuraminyl)-galactosylglucosylceramide synthase, highlighting its function in ganglioside synthesis.
Therapeutic significance:
The protein is implicated in Spastic paraplegia 26, a neurodegenerative disorder marked by progressive weakness and spasticity of the lower limbs. Understanding the role of Beta-1,4 N-acetylgalactosaminyltransferase 1 could open doors to potential therapeutic strategies for this condition, offering hope for targeted treatments.